CEO: Joshua T. Brumm
Employees: 41
IPO: Jan 10, 2014
Prijs
€ 18,37
Verandering
▲ € 1,75
10,53%
Marktkapitalisatie
506,22M
Dagbereik
€ 17,00
€ 18,43
52-Weeksbereik
€ 8,72
€ 29,00
Volume
199.217
50D / 200D Gem.
€ 11,37
€ 12,68
Vorige Slotkoers
€ 16,62
Quick Summary
Belangrijkste Punten
Revenue grew 74,87% annually over 5 years — strong growth
Debt/Equity of 0,01 — conservative balance sheet
Negative free cash flow of -72,45M
PEG of 0,07 suggests growth is underpriced
Capital efficient — spends only 8,47% of revenue on capex
Groei
Revenue Growth (5Y)
74,87%
Boven sectorgemiddelde (9,58%)
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-143,95%
Onder sectorgemiddelde (3,68%)
ROIC-55,93%
Net Margin-1382,72%
Op. Margin-1407,52%
Veiligheid
Debt / Equity
0,01
Onder sectorgemiddelde (0,24)
Current Ratio6,56
Interest Coverage-69,85
Waardering
P/E Ratio
-3,38
Onder sectorgemiddelde (0,23)
Forward P/EN/A
P/B Ratio2,49
EV/EBITDAN/A
Dividend Yield0,00%
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (635 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -3,4 | 0,2 |
| P/B | 2,5 | 2,9 |
| ROE % | -144,0 | 3,7 |
| Net Margin % | -1382,7 | 3,9 |
| Rev Growth 5Y % | 74,9 | 9,6 |
| D/E | 0,0 | 0,2 |
Dividend History
Yield
0,00%
Payout Ratio
0,00%
Growth (3Y)
N/A
Growth (5Y)
N/A
No dividend history available.
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | 3193,02% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 74,87% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 10,84M | Net Income (TTM) | -149,94M |
| ROE | -143,95% | ROA | -62,40% |
| Gross Margin | 99,23% | Operating Margin | -1407,52% |
| Net Margin | -1382,72% | Free Cash Flow (TTM) | -72,45M |
| ROIC | -55,93% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,01 | Current Ratio | 6,56 |
| Interest Coverage | -69,85 | ||
| Dividends | |||
| Dividend Yield | 0,00% | Payout Ratio | 0,00% |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -3,38 | Forward P/E | N/A |
| P/B Ratio | 2,49 | P/S Ratio | 46,68 |
| PEG Ratio | 0,07 | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -14,31% | ||
| Market Cap | 506,22M | Enterprise Value | 294,67M |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 10,84M | 0,0 | 10.000,0 | 75.000,0 | 1,16M |
| Net Income | -149,94M | -71,47M | -36,90M | -46,69M | -63,43M |
| EPS (Diluted) | 0,02 | -0,59 | -0,58 | -0,89 | -1,23 |
| Gross Profit | 10,76M | -35.174,0 | 10.000,0 | 75.000,0 | 1,16M |
| Operating Income | -152,63M | -68,76M | -39,28M | -47,40M | -63,45M |
| EBITDA | -149,67M | 0,0 | -39,12M | -47,20M | -63,18M |
| R&D Expenses | 138,09M | 56,14M | 20,07M | 28,39M | 47,49M |
| SG&A Expenses | 25,39M | 12,63M | 19,21M | 19,09M | 17,12M |
| D&A | 84.000,0 | 68,76M | 153.301,0 | 207.145,0 | 264.600,0 |
| Interest Expense | 2,19M | 0,0 | 0,0 | 0,0 | 0,0 |
| Income Tax | -2,00M | 0,0 | 0,0 | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 240,29M | 35,62M | 45,32M | 51,81M | 94,35M |
| Total Liabilities | 37,28M | 51,10M | 6,90M | 8,88M | 12,74M |
| Shareholders' Equity | 203,01M | 5,31M | 38,41M | 42,93M | 81,60M |
| Total Debt | 1,64M | 37,48M | 808.402,0 | 918.555,0 | 1,92M |
| Cash & Equivalents | 213,19M | 34,77M | 41,79M | 47,87M | 90,25M |
| Current Assets | 236,66M | 34,80M | 43,79M | 50,71M | 90,79M |
| Current Liabilities | 36,07M | 9,61M | 6,84M | 8,88M | 11,82M |